{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T01:41:13Z","timestamp":1785030073978,"version":"3.55.0"},"reference-count":76,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CYTEA BIO","award":["22\/0165"],"award-info":[{"award-number":["22\/0165"]}]},{"name":"CYTEA BIO","award":["DOS0151440"],"award-info":[{"award-number":["DOS0151440"]}]},{"name":"CYTEA BIO","award":["DOS0151444"],"award-info":[{"award-number":["DOS0151444"]}]},{"name":"MedXCell","award":["22\/0165"],"award-info":[{"award-number":["22\/0165"]}]},{"name":"MedXCell","award":["DOS0151440"],"award-info":[{"award-number":["DOS0151440"]}]},{"name":"MedXCell","award":["DOS0151444"],"award-info":[{"award-number":["DOS0151444"]}]},{"name":"TTM factory of the SATT AxLR technology transfer office","award":["22\/0165"],"award-info":[{"award-number":["22\/0165"]}]},{"name":"TTM factory of the SATT AxLR technology transfer office","award":["DOS0151440"],"award-info":[{"award-number":["DOS0151440"]}]},{"name":"TTM factory of the SATT AxLR technology transfer office","award":["DOS0151444"],"award-info":[{"award-number":["DOS0151444"]}]},{"DOI":"10.13039\/100016308","name":"BpiFrance deeptech development","doi-asserted-by":"publisher","award":["22\/0165"],"award-info":[{"award-number":["22\/0165"]}],"id":[{"id":"10.13039\/100016308","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016308","name":"BpiFrance deeptech development","doi-asserted-by":"publisher","award":["DOS0151440"],"award-info":[{"award-number":["DOS0151440"]}],"id":[{"id":"10.13039\/100016308","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016308","name":"BpiFrance deeptech development","doi-asserted-by":"publisher","award":["DOS0151444"],"award-info":[{"award-number":["DOS0151444"]}],"id":[{"id":"10.13039\/100016308","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Glioblastomas (GBMs) are lethal brain tumors in which EGFR gene amplification or mutation is frequently detected and is associated with poor prognosis. The standard of care is maximal resection followed by chemotherapy and radiation. Over the last twenty years, marginal improvements in patient survival have been achieved mainly through surgical techniques and the more accurate use of radiation. In this study, umbilical cord blood-derived and expanded human allogeneic natural killer (eNK) cells were pre-complexed to an Fc-engineered anti-EGFR monoclonal antibody (Pin-EGFR) to create Pin-EGFR-armed eNK cells. Pin-EGFR-armed eNK cells showed in vitro persistence of mAb anchoring. This arming process mediated specific, rapid and potent NK cell-redirected cytotoxicity against GBM cell lines and patient-derived cells in models consistent with the pathophysiological conditions of GBM. These results demonstrate the potential of Pin-EGFR-armed eNK cells to be an effective therapy against GBM cell lines in vitro. This product represents a promising strategy to directly target residual tumor tissue remaining at and beyond the resection margins immediately following GBM surgery to improve patient care.<\/jats:p>","DOI":"10.3390\/cells14040254","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T09:36:05Z","timestamp":1739266565000},"page":"254","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["In Vitro Evaluation of Genetically Unmodified Ligand-Armed Allogeneic Natural Killer Cells to Treat EGFR-Positive Glioblastoma"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8661-9557","authenticated-orcid":false,"given":"Hortense","family":"Courot","sequence":"first","affiliation":[{"name":"CYTEA BIO, 34790 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Rigal","sequence":"additional","affiliation":[{"name":"CYTEA BIO, 34790 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6229-1160","authenticated-orcid":false,"given":"Nawfel","family":"Adib","sequence":"additional","affiliation":[{"name":"CYTEA BIO, 34790 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Criton","sequence":"additional","affiliation":[{"name":"CYTEA BIO, 34790 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Cookson","sequence":"additional","affiliation":[{"name":"MedXCell, 1820 Montreux, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1166-8391","authenticated-orcid":false,"given":"B\u00e9n\u00e9dicte","family":"Fauvel","sequence":"additional","affiliation":[{"name":"CYTEA BIO, 34790 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessy","family":"Presumey","sequence":"additional","affiliation":[{"name":"CYTEA BIO, 34790 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noz150","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012\u20132016","volume":"21","author":"Ostrom","year":"2019","journal-title":"Neuro Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.6004\/jnccn.2023.0002","article-title":"NCCN Guidelines\u00ae Insights: Central Nervous System Cancers, Version 2.2022: Featured Updates to the NCCN Guidelines","volume":"21","author":"Horbinski","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1158\/1055-9965.EPI-14-0275","article-title":"Epidemiologic and Molecular Prognostic Review of Glioblastoma","volume":"23","author":"Thakkar","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.nec.2024.08.007","article-title":"Supramarginal Resection of Glioblastoma: A Review","volume":"36","author":"Goethe","year":"2025","journal-title":"Neurosurg. Clin. N. Am."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Haddad, A.F., Young, J.S., Morshed, R.A., and Berger, M.S. (2022). FLAIRectomy: Resecting beyond the Contrast Margin for Glioblastoma. Brain Sci., 12.","DOI":"10.3390\/brainsci12050544"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.5114\/pjr\/192044","article-title":"The Peritumoral Brain Zone in Glioblastoma: A Review of the Pretreatment Approach","volume":"89","author":"Bujko","year":"2024","journal-title":"Pol. J. Radiol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Alharbi, K.S., Javed Shaikh, M.A., Afzal, O., Alfawaz Altamimi, A.S., Almalki, W.H., Alzarea, S.I., Kazmi, I., Al-Abbasi, F.A., Singh, S.K., and Dua, K. (2022). An Overview of Epithelial Growth Factor Receptor (EGFR) Inhibitors in Cancer Therapy. Chem.-Biol. Interact., 366.","DOI":"10.1016\/j.cbi.2022.110108"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The Somatic Genomic Landscape of Glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Oprita, A., Baloi, S.-C., Staicu, G.-A., Alexandru, O., Tache, D.E., Danoiu, S., Micu, E.S., and Sevastre, A.-S. (2021). Updated Insights on EGFR Signaling Pathways in Glioma. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020587"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/neuonc\/noab231","article-title":"The EGFRvIII Transcriptome in Glioblastoma: A Meta-Omics Analysis","volume":"24","author":"Hoogstrate","year":"2022","journal-title":"Neuro-Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/annonc\/mdp032","article-title":"Stratified Phase II Trial of Cetuximab in Patients with Recurrent High-Grade Glioma","volume":"20","author":"Neyns","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A Single Dose of Peripherally Infused EGFRvIII-Directed CAR T Cells Mediates Antigen Loss and Induces Adaptive Resistance in Patients with Recurrent Glioblastoma","volume":"9","author":"Nasrallah","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/CJI.0000000000000260","article-title":"Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor\u2013Transduced T Cells Targeting EGFRvIII in Patients with Glioblastoma","volume":"42","author":"Goff","year":"2019","journal-title":"J. Immunother."},{"key":"ref_14","first-page":"3355","article-title":"Monoclonal Antibody Cetuximab Binds to and Down-Regulates Constitutively Activated Epidermal Growth Factor Receptor vIII on the Cell Surface","volume":"27","author":"Patel","year":"2007","journal-title":"Anticancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/s41590-019-0433-y","article-title":"Mechanisms of Immunotherapy Resistance: Lessons from Glioblastoma","volume":"20","author":"Jackson","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Adhikaree, J., Moreno-Vicente, J., Kaur, A.P., Jackson, A.M., and Patel, P.M. (2020). Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma. Cells, 9.","DOI":"10.3390\/cells9020263"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Breznik, B., Ko, M.-W., Tse, C., Chen, P.-C., Senjor, E., Majc, B., Habi\u010d, A., Angelillis, N., Novak, M., and \u017dupunski, V. (2022). Infiltrating Natural Killer Cells Bind, Lyse and Increase Chemotherapy Efficacy in Glioblastoma Stem-like Tumorospheres. Commun. Biol., 5.","DOI":"10.1038\/s42003-022-03402-z"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0165-5728(00)00221-6","article-title":"Involvement of Natural Cytotoxicity Receptors in Human Natural Killer Cell-Mediated Lysis of Neuroblastoma and Glioblastoma Cell Lines","volume":"107","author":"Sivori","year":"2000","journal-title":"J. Neuroimmunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1750-3639.2011.00515.x","article-title":"Human Glioblastoma Stem-like Cells Are More Sensitive to Allogeneic NK and T Cell-Mediated Killing Compared with Serum-Cultured Glioblastoma Cells","volume":"22","author":"Avril","year":"2012","journal-title":"Brain Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.4049\/jimmunol.0802845","article-title":"NK Cells Recognize and Kill Human Glioblastoma Cells with Stem Cell-Like Properties1","volume":"182","author":"Castriconi","year":"2009","journal-title":"J. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"7596","DOI":"10.1158\/0008-5472.CAN-04-1627","article-title":"RNA Interference Targeting Transforming Growth Factor-\u03b2 Enhances NKG2D-Mediated Antiglioma Immune Response, Inhibits Glioma Cell Migration and Invasiveness, and Abrogates Tumorigenicity In Vivo","volume":"64","author":"Friese","year":"2004","journal-title":"Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1158\/1078-0432.CCR-09-3087","article-title":"Induction of Anti-Glioma Natural Killer Cell Response Following Multiple Low-Dose Intracerebral CpG Therapy","volume":"16","author":"Alizadeh","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e2111003119","DOI":"10.1073\/pnas.2111003119","article-title":"STING Activation Promotes Robust Immune Response and NK Cell\u2013Mediated Tumor Regression in Glioblastoma Models","volume":"119","author":"Berger","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","first-page":"1861","article-title":"Autologous Natural Killer Cell Therapy for Human Recurrent Malignant Glioma","volume":"24","author":"Ishikawa","year":"2004","journal-title":"Anticancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Lim, J., Park, Y., Ahn, J.W., Sim, J., Kang, S.J., Hwang, S., Chun, J., Choi, H., Kim, S.H., and Chun, D.-H. (2021). Autologous Adoptive Immune-Cell Therapy Elicited a Durable Response with Enhanced Immune Reaction Signatures in Patients with Recurrent Glioblastoma: An Open Label, Phase I\/IIa Trial. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0247293"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Veluchamy, J.P., Kok, N., van der Vliet, H.J., Verheul, H.M.W., de Gruijl, T.D., and Spanholtz, J. (2017). The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.00631"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12943-020-01238-x","article-title":"Natural Killer Cells in Cancer Biology and Therapy","volume":"19","author":"Wu","year":"2020","journal-title":"Mol. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, Efficacy and Determinants of Response of Allogeneic CD19-Specific CAR-NK Cells in CD19+ B Cell Tumors: A Phase 1\/2 Trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.3892\/or.2014.3077","article-title":"Cetuximab-Mediated ADCC Activity Is Correlated with the Cell Surface Expression Level of EGFR but Not with the KRAS\/BRAF Mutational Status in Colorectal Cancer","volume":"31","author":"Seo","year":"2014","journal-title":"Oncol. Rep."},{"key":"ref_31","unstructured":"Chidharla, A., Parsi, M., and Kasi, A. (2025, February 07). Cetuximab, StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459293\/."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e009070","DOI":"10.1136\/jitc-2024-009070","article-title":"Generation of Non-Genetically Modified, CAR-like, NK Cells","volume":"12","author":"Rigal","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Stringer, B.W., Day, B.W., D\u2019Souza, R.C.J., Jamieson, P.R., Ensbey, K.S., Bruce, Z.C., Lim, Y.C., Goasdou\u00e9, K., Offenh\u00e4user, C., and Akg\u00fcl, S. (2019). A Reference Collection of Patient-Derived Cell Line and Xenograft Models of Proneural, Classical and Mesenchymal Glioblastoma. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-41277-z"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Regis, S., Dondero, A., Caliendo, F., Bottino, C., and Castriconi, R. (2020). NK Cell Function Regulation by TGF-\u03b2-Induced Epigenetic Mechanisms. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00311"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Slattery, K., and Gardiner, C.M. (2019). NK Cell Metabolism and TGF\u03b2\u2014Implications for Immunotherapy. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.02915"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Gol\u00e1n-Cancela, I., and Caja, L. (2024). The TGF-\u03b2 Family in Glioblastoma. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25021067"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e142116","DOI":"10.1172\/JCI142116","article-title":"Targeting the Av Integrin\/TGF-\u03b2 Axis Improves Natural Killer Cell Function against Glioblastoma Stem Cells","volume":"131","author":"Shaim","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/neuonc\/nop009","article-title":"TGF-\u03b2 Downregulates the Activating Receptor NKG2D on NK Cells and CD8+ T Cells in Glioma Patients","volume":"12","author":"Crane","year":"2010","journal-title":"Neuro-Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1073\/pnas.0730640100","article-title":"Transforming Growth Factor \u03921 Inhibits Expression of NKp30 and NKG2D Receptors: Consequences for the NK-Mediated Killing of Dendritic Cells","volume":"100","author":"Castriconi","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.4049\/jimmunol.1202693","article-title":"Neuroblastoma-Derived TGF-\u03921 Modulates the Chemokine Receptor Repertoire of Human Resting NK Cells","volume":"190","author":"Castriconi","year":"2013","journal-title":"J. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ccr.2006.11.023","article-title":"High TGF\u03b2-Smad Activity Confers Poor Prognosis in Glioma Patients and Promotes Cell Proliferation Depending on the Methylation of the PDGF-B Gene","volume":"11","author":"Bruna","year":"2007","journal-title":"Cancer Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41423-024-01145-x","article-title":"Development of NK Cell-Based Cancer Immunotherapies through Receptor Engineering","volume":"21","author":"Page","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1182\/bloodadvances.2020002547","article-title":"Next-Generation Cell Therapies: The Emerging Role of CAR-NK Cells","volume":"4","author":"Basar","year":"2020","journal-title":"Blood Adv."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Reusch, U., Ellwanger, K., Fucek, I., M\u00fcller, T., Schniegler-Mattox, U., Koch, J., and Tesar, M. (2022). Cryopreservation of Natural Killer Cells Pre-Complexed with Innate Cell Engagers. Antibodies, 11.","DOI":"10.3390\/antib11010012"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1158\/1078-0432.CCR-21-0164","article-title":"Combining AFM13, a Bispecific CD30\/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood\u2013Derived NK Cells Facilitates CAR-like Responses against CD30+ Malignancies","volume":"27","author":"Kerbauy","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Li, H.-K., Hsiao, C.-W., Yang, S.-H., Yang, H.-P., Wu, T.-S., Lee, C.-Y., Lin, Y.-L., Pan, J., Cheng, Z.-F., and Lai, Y.-D. (2021). A Novel Off-the-Shelf Trastuzumab-Armed NK Cell Therapy (ACE1702) Using Antibody-Cell-Conjugation Technology. Cancers, 13.","DOI":"10.3390\/cancers13112724"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jcyt.2020.01.003","article-title":"A Novel Antibody-Cell Conjugation Method to Enhance and Characterize Cytokine-Induced Killer Cells","volume":"22","author":"Frank","year":"2020","journal-title":"Cytotherapy"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1021\/acschembio.1c00022","article-title":"Equipping Natural Killer Cells with Cetuximab through Metabolic Glycoengineering and Bioorthogonal Reaction for Targeted Treatment of KRAS Mutant Colorectal Cancer","volume":"16","author":"Wang","year":"2021","journal-title":"ACS Chem. Biol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Alija, M., van Moer, B., Sastre, D.E., Azzam, T., Du, J.J., Trastoy, B., Callewaert, N., Sundberg, E.J., and Guerin, M.E. (2023). Modulating Antibody Effector Functions by Fc Glycoengineering. Biotechnol. Adv., 67.","DOI":"10.1016\/j.biotechadv.2023.108201"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2038531","DOI":"10.1080\/19420862.2022.2038531","article-title":"The Fab Portion of Immunoglobulin G Has Sites in the CL Domain That Interact with Fc Gamma Receptor IIIa","volume":"14","author":"Yamaguchi","year":"2022","journal-title":"mAbs"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Dixon, K.J., Wu, J., and Walcheck, B. (2021). Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK Cells. Cancers, 13.","DOI":"10.3390\/cancers13020312"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13287-022-02769-4","article-title":"Challenges to the Broad Application of Allogeneic Natural Killer Cell Immunotherapy of Cancer","volume":"13","author":"Kennedy","year":"2022","journal-title":"Stem Cell Res. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Jiang, P., Jing, S., Sheng, G., and Jia, F. (2024). The Basic Biology of NK Cells and Its Application in Tumor Immunotherapy. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1420205"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41590-020-0728-z","article-title":"The NK Cell\u2013Cancer Cycle: Advances and New Challenges in NK Cell\u2013Based Immunotherapies","volume":"21","author":"Bald","year":"2020","journal-title":"Nat. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood-2014-04-569061","article-title":"Antibody Fc Engineering Improves Frequency and Promotes Kinetic Boosting of Serial Killing Mediated by NK Cells","volume":"124","author":"Romain","year":"2014","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"6296","DOI":"10.1158\/1078-0432.CCR-12-0668","article-title":"Antibody-Dependent Cell-Mediated Cytotoxicity Overcomes NK Cell Resistance in MLL-Rearranged Leukemia Expressing Inhibitory KIR Ligands but Not Activating Ligands","volume":"18","author":"Chan","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1182\/blood-2009-01-201632","article-title":"Minimal Requirement for Induction of Natural Cytotoxicity and Intersection of Activation Signals by Inhibitory Receptors","volume":"114","author":"Bryceson","year":"2009","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming Growth Factor-\u03b2 Signaling in Immunity and Cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"109638","DOI":"10.1016\/j.cellsig.2020.109638","article-title":"Multifaceted Transforming Growth Factor-Beta (TGF\u03b2) Signalling in Glioblastoma","volume":"72","author":"Birch","year":"2020","journal-title":"Cell. Signal."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3892\/ol.2022.13253","article-title":"Cell-Based Immunotherapy of Glioblastoma Multiforme","volume":"23","author":"Bryukhovetskiy","year":"2022","journal-title":"Oncol. Lett."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1016\/j.ymthe.2024.07.020","article-title":"Armored Bicistronic CAR T Cells with Dominant-Negative TGF-\u03b2 Receptor II to Overcome Resistance in Glioblastoma","volume":"32","author":"Li","year":"2024","journal-title":"Mol. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jcyt.2022.04.001","article-title":"Comparable Transforming Growth Factor Beta-Mediated Immune Suppression in Ex Vivo-Expanded Natural Killer Cells from Cord Blood and Peripheral Blood: Implications for Adoptive Immunotherapy","volume":"24","author":"Chaudhry","year":"2022","journal-title":"Cytotherapy"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1158\/1078-0432.CCR-18-3183","article-title":"Engineering the TGF\u03b2 Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma","volume":"25","author":"Burga","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e1108513","DOI":"10.1080\/2162402X.2015.1108513","article-title":"The Multidrug-Resistance Transporter Abcc3 Protects NK Cells from Chemotherapy in a Murine Model of Malignant Glioma","volume":"5","author":"Pessina","year":"2015","journal-title":"Oncoimmunology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3892\/ol.2024.14573","article-title":"Local Therapy in Glioma: An Evolving Paradigm from History to Horizons (Review)","volume":"28","author":"Ius","year":"2024","journal-title":"Oncol. Lett."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41582-022-00621-0","article-title":"Advances in Local Therapy for Glioblastoma\u2014Taking the Fight to the Tumour","volume":"18","author":"Nieland","year":"2022","journal-title":"Nat. Rev. Neurol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11910-024-01338-x","article-title":"Strategies to Improve Drug Delivery Across the Blood\u2013Brain Barrier for Glioblastoma","volume":"24","author":"Narsinh","year":"2024","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ymthe.2017.10.002","article-title":"Optimization of IL13R\u03b12-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-Tumor Efficacy against Glioblastoma","volume":"26","author":"Brown","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/1078-0432.CCR-17-2041","article-title":"Regional Delivery of Chimeric Antigen Receptor\u2013Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain","volume":"24","author":"Priceman","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41591-020-0821-8","article-title":"Locoregionally Administered B7-H3-Targeted CAR T Cells for Treatment of Atypical Teratoid\/Rhabdoid Tumors","volume":"26","author":"Theruvath","year":"2020","journal-title":"Nat. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/neuonc\/noae063","article-title":"Locoregional Delivery of Chimeric Antigen Receptor-T Cells: Breaking the Spell in Glioblastoma?","volume":"26","author":"Geurts","year":"2024","journal-title":"Neuro Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e001743","DOI":"10.1136\/jitc-2020-001743","article-title":"Comparison of Non-Myeloablative Lymphodepleting Preconditioning Regimens in Patients Undergoing Adoptive T Cell Therapy","volume":"9","author":"Nissani","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1146\/annurev-pathol-020117-043720","article-title":"New Insights into Graft-Versus-Host Disease and Graft Rejection","volume":"13","author":"Perkey","year":"2018","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"10441","DOI":"10.1073\/pnas.1902566116","article-title":"Generation of Hypoimmunogenic Human Pluripotent Stem Cells","volume":"116","author":"Han","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ceb.2008.12.010","article-title":"ErbB Receptors and Signaling Pathways in Cancer","volume":"21","author":"Hynes","year":"2009","journal-title":"Curr. Opin. Cell Biol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/4\/254\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:30:56Z","timestamp":1760027456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/4\/254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":76,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["cells14040254"],"URL":"https:\/\/doi.org\/10.3390\/cells14040254","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]}}}